{"DataElement":{"publicId":"2944967","version":"1","preferredName":"Patient T Stage Breast Carcinoma Clinical Trial Eligibility Criteria Status","preferredDefinition":"the status of a patient's breast carcinoma T stage in relation to clinical trial eligibility.","longName":"PT_TSTG_BR_CTEC_STAT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2944964","version":"1","preferredName":"Patient T Stage Breast Carcinoma Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to carcinoma of the breast (a carcinoma arising from the breast, most commonly the terminal ductal-lobular unit) T stage (T refers to the extent of tumor involvement at the primary site) and determining whether a patient/participant is suitable for enrollment in a study according to protocol criteria and procedures.","longName":"PT_TSTG_BRCA_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2944962","version":"1","preferredName":"T Stage Breast Carcinoma Clinical Trial Eligibility Criteria","preferredDefinition":"One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25728:C4872:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7453771D-200B-90D4-E040-BB89AD436C66","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"ONEDATA","dateModified":"2009-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7453771D-201C-90D4-E040-BB89AD436C66","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2944965","version":"1","preferredName":"T Stage Breast Eligibility Status","preferredDefinition":"the status of breast carcinoma T stage in relation to clinical trial eligibility.","longName":"TSTG_BRST_ELIG_STAT","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T4a-c","valueDescription":"T4a-c","ValueMeaning":{"publicId":"2944966","version":"1","preferredName":"T4a-c","longName":"2944966","preferredDefinition":"T4a-c","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7453771D-204C-90D4-E040-BB89AD436C66","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7453771D-2065-90D4-E040-BB89AD436C66","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"ONEDATA","dateModified":"2009-09-24","deletedIndicator":"No"},{"value":"T3","valueDescription":"T3","ValueMeaning":{"publicId":"2560165","version":"1","preferredName":"T3","longName":"2560165v1.00","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T3 TNM Finding","conceptCode":"C48728","definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B812-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7453771D-206F-90D4-E040-BB89AD436C66","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"ONEDATA","dateModified":"2009-09-24","deletedIndicator":"No"},{"value":"T2","valueDescription":"T2","ValueMeaning":{"publicId":"2560156","version":"1","preferredName":"T2","longName":"2560156v1.00","preferredDefinition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B809-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7453771D-207A-90D4-E040-BB89AD436C66","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"ONEDATA","dateModified":"2009-09-24","deletedIndicator":"No"},{"value":"T4","valueDescription":"T4","ValueMeaning":{"publicId":"2560174","version":"1","preferredName":"T4","longName":"2560174v1.00","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T4 TNM Finding","conceptCode":"C48732","definition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B81B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"808698C7-E798-2431-E040-BB89AD433218","beginDate":"2010-02-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-02-26","modifiedBy":"ONEDATA","dateModified":"2010-02-26","deletedIndicator":"No"},{"value":"T1-2","valueDescription":"T1-2","ValueMeaning":{"publicId":"3626399","version":"1","preferredName":"T1-2","longName":"3626399","preferredDefinition":"T1-2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE7A5C64-1B19-B423-E040-BB89AD433A08","latestVersionIndicator":"Yes","beginDate":"2012-11-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CE7A5C64-1B32-B423-E040-BB89AD433A08","beginDate":"2012-11-14","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2012-11-14","modifiedBy":"ONEDATA","dateModified":"2012-11-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7453771D-2038-90D4-E040-BB89AD436C66","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"ZIEGLERK","dateModified":"2012-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]}],"AlternateNames":[{"name":"PT_TSTG_BR_CTEC_STAT","type":"USED_BY","context":"CTEP"},{"name":"PT_TSTG_BR_CTEC_STAT","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Clinical T Stage","type":"Preferred Question Text","description":"Clinical T Stage","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Clinical tumor stage","url":null,"context":"CTEP"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7453519B-08A0-45B4-E040-BB89AD4308B9","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"FORMBUILDER","dateModified":"2014-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}